Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome
Aim. To investigate clinical effectiveness of imidazoline receptor agonist, moxonidine, in arterial hypertension (AH) treatment among women with menopausal metabolic syndrome (MMS). Material and methods. In total, 38 women (mean age 51,4±0,3 years) with MMS received moxonidine (0,2-0,6 mg/d, accordi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2007-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1278 |
| _version_ | 1827064094932336640 |
|---|---|
| author | V. V. Trusov K. V. Aksenov T. E. Chernyshova |
| author_facet | V. V. Trusov K. V. Aksenov T. E. Chernyshova |
| author_sort | V. V. Trusov |
| collection | DOAJ |
| description | Aim. To investigate clinical effectiveness of imidazoline receptor agonist, moxonidine, in arterial hypertension (AH) treatment among women with menopausal metabolic syndrome (MMS). Material and methods. In total, 38 women (mean age 51,4±0,3 years) with MMS received moxonidine (0,2-0,6 mg/d, according to antihypertensive effect) for 6 months. Detailed examination included: 24-hour blood pressure monitoring (BPM), electrocardiography (ECG), microcirculation and endothelial function, vasoactive hormone levels, and insulin resistance (HOMA IR) assessment. Carbohydrate and lipid metabolism parameters were also analyzed. None of the participants received hormone replacement therapy. Results. Moxonidine therapy was associated with decreased mean systolic and diastolic BP levels (р<0,01). Circadian BP profiles improved, and BP variability reduced (р<0,05), as well as morning BP surge (p<0,01). Six-month moxonidine treatment resulted in microcirculation improvement. Positive dynamics of endothelium-dependent brachial artery vasodilatation in reactive hyperemia test was observed (p<0,05). Moxonidine therapy was also associated with insulin resistance decrease (p<0,05), and body mass index reduction by 6 months. Conclusion. Moxonidine can be recommended as a basal antihypertensive medication in MMS patients. |
| first_indexed | 2024-04-10T03:39:36Z |
| format | Article |
| id | doaj.art-88e6f40703e74241b4b6bb45a97e04d7 |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2025-03-19T22:41:41Z |
| publishDate | 2007-08-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-88e6f40703e74241b4b6bb45a97e04d72024-10-17T12:21:25Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252007-08-01641319989Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndromeV. V. Trusov0K. V. Aksenov1T. E. Chernyshova2Izhevsk State Medical Academy, IzhevskIzhevsk State Medical Academy, IzhevskIzhevsk State Medical Academy, IzhevskAim. To investigate clinical effectiveness of imidazoline receptor agonist, moxonidine, in arterial hypertension (AH) treatment among women with menopausal metabolic syndrome (MMS). Material and methods. In total, 38 women (mean age 51,4±0,3 years) with MMS received moxonidine (0,2-0,6 mg/d, according to antihypertensive effect) for 6 months. Detailed examination included: 24-hour blood pressure monitoring (BPM), electrocardiography (ECG), microcirculation and endothelial function, vasoactive hormone levels, and insulin resistance (HOMA IR) assessment. Carbohydrate and lipid metabolism parameters were also analyzed. None of the participants received hormone replacement therapy. Results. Moxonidine therapy was associated with decreased mean systolic and diastolic BP levels (р<0,01). Circadian BP profiles improved, and BP variability reduced (р<0,05), as well as morning BP surge (p<0,01). Six-month moxonidine treatment resulted in microcirculation improvement. Positive dynamics of endothelium-dependent brachial artery vasodilatation in reactive hyperemia test was observed (p<0,05). Moxonidine therapy was also associated with insulin resistance decrease (p<0,05), and body mass index reduction by 6 months. Conclusion. Moxonidine can be recommended as a basal antihypertensive medication in MMS patients.https://cardiovascular.elpub.ru/jour/article/view/1278moxonidinearterial hypertensionmetabolic syndromemenopause |
| spellingShingle | V. V. Trusov K. V. Aksenov T. E. Chernyshova Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome Кардиоваскулярная терапия и профилактика moxonidine arterial hypertension metabolic syndrome menopause |
| title | Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome |
| title_full | Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome |
| title_fullStr | Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome |
| title_full_unstemmed | Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome |
| title_short | Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome |
| title_sort | moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome |
| topic | moxonidine arterial hypertension metabolic syndrome menopause |
| url | https://cardiovascular.elpub.ru/jour/article/view/1278 |
| work_keys_str_mv | AT vvtrusov moxonidineforarterialhypertensiontreatmentinmenopausalwomenwithmetabolicsyndrome AT kvaksenov moxonidineforarterialhypertensiontreatmentinmenopausalwomenwithmetabolicsyndrome AT techernyshova moxonidineforarterialhypertensiontreatmentinmenopausalwomenwithmetabolicsyndrome |